{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,26]],"date-time":"2026-03-26T14:07:39Z","timestamp":1774534059195,"version":"3.50.1"},"reference-count":26,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2025,2,1]],"date-time":"2025-02-01T00:00:00Z","timestamp":1738368000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,2,1]],"date-time":"2025-02-01T00:00:00Z","timestamp":1738368000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,10,25]],"date-time":"2024-10-25T00:00:00Z","timestamp":1729814400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","celltherapyjournal.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Cytotherapy"],"published-print":{"date-parts":[[2025,2]]},"DOI":"10.1016\/j.jcyt.2024.10.006","type":"journal-article","created":{"date-parts":[[2024,10,25]],"date-time":"2024-10-25T00:46:00Z","timestamp":1729817160000},"page":"247-257","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":5,"title":["Optimizing the procedure for manufacturing clinical-grade genetically manipulated natural killer cells for adoptive immunotherapy"],"prefix":"10.1016","volume":"27","author":[{"given":"Haolong","family":"Lin","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0001-3424-5407","authenticated-orcid":false,"given":"Shanwei","family":"Ye","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shujia","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tong","family":"Ge","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dengju","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Liang","family":"Huang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Li","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wei","family":"Mu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"12","key":"10.1016\/j.jcyt.2024.10.006_bib0001","doi-asserted-by":"crossref","first-page":"1994","DOI":"10.1038\/s41590-023-01659-y","article-title":"Forks in the road for CAR T and CAR NK cell cancer therapies","volume":"24","author":"Dagher","year":"2023","journal-title":"Nat Immunol"},{"issue":"7949","key":"10.1016\/j.jcyt.2024.10.006_bib0002","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1038\/s41586-023-05707-3","article-title":"CAR immune cells: design principles, resistance and the next generation","volume":"614","author":"Labanieh","year":"2023","journal-title":"Nature"},{"issue":"2","key":"10.1016\/j.jcyt.2024.10.006_bib0003","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1038\/s41571-020-0426-7","article-title":"Exploring the NK cell platform for cancer immunotherapy","volume":"18","author":"Myers","year":"2021","journal-title":"Nat Rev Clin Oncol"},{"issue":"8","key":"10.1016\/j.jcyt.2024.10.006_bib0004","doi-asserted-by":"crossref","first-page":"3051","DOI":"10.1182\/blood-2004-07-2974","article-title":"Successful adoptive transfer and in vivo expansion of human haploidentical NK cells in patients with cancer","volume":"105","author":"Miller","year":"2005","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.jcyt.2024.10.006_bib0005","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1186\/s13045-022-01382-5","article-title":"Natural killer cells in clinical development as non-engineered, engineered, and combination therapies","volume":"15","author":"Lamers-Kok","year":"2022","journal-title":"J Hematol Oncol"},{"issue":"6","key":"10.1016\/j.jcyt.2024.10.006_bib0006","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1056\/NEJMoa1910607","article-title":"Use of CAR-transduced natural killer cells in CD19-positive lymphoid tumors","volume":"382","author":"Liu","year":"2020","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jcyt.2024.10.006_bib0007","doi-asserted-by":"crossref","first-page":"2873","DOI":"10.3389\/fimmu.2019.02873","article-title":"Efficient and robust NK-cell transduction with baboon envelope pseudotyped lentivector","volume":"10","author":"Colamartino","year":"2019","journal-title":"Front Immunol"},{"issue":"1","key":"10.1016\/j.jcyt.2024.10.006_bib0008","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1038\/s41392-022-00898-z","article-title":"T cells expressing CD5\/CD7 bispecific chimeric antigen receptors with fully human heavy-chain-only domains mitigate tumor antigen escape","volume":"7","author":"Dai","year":"2022","journal-title":"Signal Transduct Target Ther"},{"issue":"8","key":"10.1016\/j.jcyt.2024.10.006_bib0009","doi-asserted-by":"crossref","first-page":"1221","DOI":"10.1182\/blood-2014-02-558163","article-title":"Baboon envelope pseudotyped LVs outperform VSV-G-LVs for gene transfer into early-cytokine-stimulated and resting HSCs","volume":"124","author":"Girard-Gagnepain","year":"2014","journal-title":"Blood"},{"issue":"8","key":"10.1016\/j.jcyt.2024.10.006_bib0010","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1038\/s41573-022-00413-7","article-title":"Harnessing natural killer cells for cancer immunotherapy: dispatching the first responders","volume":"21","author":"Maskalenko","year":"2022","journal-title":"Nat Rev Drug Discov"},{"issue":"11","key":"10.1016\/j.jcyt.2024.10.006_bib0011","doi-asserted-by":"crossref","first-page":"1670","DOI":"10.1182\/blood.2021013972","article-title":"Donor memory-like NK cells persist and induce remissions in pediatric patients with relapsed AML after transplant","volume":"139","author":"Bednarski","year":"2022","journal-title":"Blood"},{"issue":"11","key":"10.1016\/j.jcyt.2024.10.006_bib0012","doi-asserted-by":"crossref","DOI":"10.1172\/JCI154334","article-title":"Expansion, persistence, and efficacy of donor memory-like NK cells infused for posttransplant relapse","volume":"132","author":"Shapiro","year":"2022","journal-title":"J Clin Invest"},{"issue":"3","key":"10.1016\/j.jcyt.2024.10.006_bib0013","doi-asserted-by":"crossref","first-page":"772","DOI":"10.1038\/s41591-023-02785-8","article-title":"Safety, efficacy and determinants of response of allogeneic CD19-specific CAR-NK cells in CD19(+) B cell tumors: a phase 1\/2 trial","volume":"30","author":"Marin","year":"2024","journal-title":"Nat Med"},{"issue":"3","key":"10.1016\/j.jcyt.2024.10.006_bib0014","doi-asserted-by":"crossref","DOI":"10.3390\/cancers13030577","article-title":"Optimizing the procedure to manufacture clinical-grade NK cells for adoptive immunotherapy","volume":"13","author":"Fern\u00e1ndez","year":"2021","journal-title":"Cancers (Basel)"},{"issue":"13","key":"10.1016\/j.jcyt.2024.10.006_bib0015","doi-asserted-by":"crossref","DOI":"10.3390\/cells13131148","article-title":"A critical role of culture medium selection in maximizing the purity and expansion of natural killer cells","volume":"13","author":"Kusch","year":"2024","journal-title":"Cells"},{"issue":"6","key":"10.1016\/j.jcyt.2024.10.006_bib0016","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1016\/j.jcyt.2020.02.002","article-title":"Evaluation of serum-free media formulations in feeder cell-stimulated expansion of natural killer cells","volume":"22","author":"Moseman","year":"2020","journal-title":"Cytotherapy"},{"issue":"1","key":"10.1016\/j.jcyt.2024.10.006_bib0017","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1186\/s13045-020-01014-w","article-title":"NK cell-based cancer immunotherapy: from basic biology to clinical development","volume":"14","author":"Liu","year":"2021","journal-title":"J Hematol Oncol"},{"issue":"5","key":"10.1016\/j.jcyt.2024.10.006_bib0018","doi-asserted-by":"crossref","first-page":"836","DOI":"10.3324\/haematol.2013.087536","article-title":"Leukemia-induced phenotypic and functional defects in natural killer cells predict failure to achieve remission in acute myeloid leukemia","volume":"99","author":"Stringaris","year":"2014","journal-title":"Haematologica"},{"issue":"5","key":"10.1016\/j.jcyt.2024.10.006_bib0019","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2021-004244","article-title":"Targeting CISH enhances natural cytotoxicity receptor signaling and reduces NK cell exhaustion to improve solid tumor immunity","volume":"10","author":"Bernard","year":"2022","journal-title":"J Immunother Cancer"},{"issue":"1","key":"10.1016\/j.jcyt.2024.10.006_bib0020","doi-asserted-by":"crossref","first-page":"e14073","DOI":"10.15252\/emmm.202114073","article-title":"Modulation of intrinsic inhibitory checkpoints using nano-carriers to unleash NK cell activity","volume":"14","author":"Biber","year":"2022","journal-title":"EMBO Mol Med"},{"issue":"3","key":"10.1016\/j.jcyt.2024.10.006_bib0021","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1158\/2326-6066.CIR-19-0749","article-title":"Control of metastases via myeloid CD39 and NK cell effector function","volume":"8","author":"Yan","year":"2020","journal-title":"Cancer Immunol Res"},{"issue":"30","key":"10.1016\/j.jcyt.2024.10.006_bib0022","doi-asserted-by":"crossref","first-page":"eadd6997","DOI":"10.1126\/sciadv.add6997","article-title":"Loss of metabolic fitness drives tumor resistance after CAR-NK cell therapy and can be overcome by cytokine engineering","volume":"9","author":"Li","year":"2023","journal-title":"Sci Adv"},{"issue":"1","key":"10.1016\/j.jcyt.2024.10.006_bib0023","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1186\/s13045-021-01083-5","article-title":"Chimeric antigen receptor natural killer (CAR-NK) cell design and engineering for cancer therapy","volume":"14","author":"Gong","year":"2021","journal-title":"J Hematol Oncol"},{"issue":"9","key":"10.1016\/j.jcyt.2024.10.006_bib0024","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1016\/j.jcyt.2021.04.010","article-title":"Transient blockade of TBK1\/IKK\u03b5 allows efficient transduction of primary human natural killer cells with vesicular stomatitis virus G-pseudotyped lentiviral vectors","volume":"23","author":"Chockley","year":"2021","journal-title":"Cytotherapy"},{"key":"10.1016\/j.jcyt.2024.10.006_bib0025","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1016\/j.omtm.2019.11.011","article-title":"Production of lentiviral vectors using suspension cells grown in serum-free media","volume":"17","author":"Bauler","year":"2020","journal-title":"Molecular therapy Methods & clinical development"},{"issue":"3","key":"10.1016\/j.jcyt.2024.10.006_bib0026","doi-asserted-by":"crossref","DOI":"10.1084\/jem.20201529","article-title":"A robust platform for expansion and genome editing of primary human natural killer cells","volume":"218","author":"Huang","year":"2021","journal-title":"J Exp Med"}],"container-title":["Cytotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1465324924009022?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1465324924009022?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,1,19]],"date-time":"2025-01-19T22:57:54Z","timestamp":1737327474000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1465324924009022"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2]]},"references-count":26,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2025,2]]}},"alternative-id":["S1465324924009022"],"URL":"https:\/\/doi.org\/10.1016\/j.jcyt.2024.10.006","relation":{},"ISSN":["1465-3249"],"issn-type":[{"value":"1465-3249","type":"print"}],"subject":[],"published":{"date-parts":[[2025,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Optimizing the procedure for manufacturing clinical-grade genetically manipulated natural killer cells for adoptive immunotherapy","name":"articletitle","label":"Article Title"},{"value":"Cytotherapy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jcyt.2024.10.006","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 International Society for Cell & Gene Therapy. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}